Antireflux mucosectomy (ARMS) and antireflux mucosal ablation (ARMA) for gastroesophageal reflux disease: a systematic review and meta-analysis
| Autor: | Enrique Rodríguez de Santiago, Carlos Teruel Sanchez-Vegazo, Beatriz Peñas, Yuto Shimamura, Mayo Tanabe, Noelia Álvarez-Díaz, Sofía Parejo, Sumi Kazuya, Natalia Marcos-Carrasco, Enrique Vazquez-Sequeiros, Haruhiro Inoue, Agustín Albillos |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Endoscopy International Open, Vol 09, Iss 11, Pp E1740-E1751 (2021) |
| Druh dokumentu: | article |
| ISSN: | 2364-3722 2196-9736 |
| DOI: | 10.1055/a-1552-3239 |
| Popis: | Background and study aims Antireflux mucosectomy (ARMS) and antireflux mucosal ablation (ARMA) are new endoscopic procedures for patients with gastroesophageal reflux disease (GERD). We conducted a meta-analysis to systematically assess the feasibility, clinical success, and safety of these procedures. Patients and methods We searched Embase, PubMed, and Cochrane Central from inception to October 2020. Overlapping reports, animal studies, and case reports were excluded. Our primary outcomes were clinical success and adverse events (AEs). Secondary outcomes included technical success, endoscopic esophagitis, 24-hour pH monitoring, and proton pump inhibitor (PPI) use. A random effects model was used to pool data. Results In total, 15 nonrandomized studies (12 ARMS, n = 331; 3 ARMA, n = 130) were included; 10 were conducted in patients with refractory GERD. The technical success rate was 100 %. The pooled short-term (first assessment within the first 6 months), 1-year, and 3-year clinical success rates were 78 % (95 % confidence interval [95 %CI] 70 %–85 %), 72% (95 %CI 47 %–92 %), and 73 % (95 %CI 65 %–81 %), respectively. ARMS and ARMA yielded similar clinical success. The proportion of patients off PPIs at 1 year was 64 % (95 %CI 52 %–75 %). There were significant drops (P |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|